Domain Therapeutics opens Montreal subsidiary

Guest Contributor
February 10, 2014

Domain Therapeutics, Strasbourg France, has announced the opening of a North American subsidiary at the NEOMED Institute in Montreal. The move follows a licensing and partnership agreement with the Univ of Montreal, its commercialization arm — Institute for Research in Immunology and Cancer (IRIC) — and McGill Univ. The Montreal unit will focus on developing biosensor technology related to G protein-couple receptors (GPCRs), developed by a molecular pharmacology team led by Dr Michel Bouvier at IRIC. Domain is a strategic partner of pharmaceutical companies seeking new GPCR drug candidates in all major therapeutic fields. It's hoped the Montreal operation will lead to strategic relationships with North American companies. Last year's partnership agreement with U of M involves an upfront signing payment, an annual access fee for new technology and royalties earned from sales of drugs and screening services....

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.